Skip to content
Trial Eligibility
Menu

A Study of Ivonescimab in People With Non-Small Cell Lung Cancer

NCT07594522

This study is recruiting at 7 US sites in 2 states, according to its ClinicalTrials.gov record last updated .

Summary

The researchers are doing this study to find out whether ivonescimab after receiving standard stereotactic body radiotherapy (SBRT) is an effective treatment in people with Non-Small Cell Lung Cancer (NSCLC).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Non-Small Cell Lung Cancer

Eligibility basics and study details

Study type
Interventional
Phase
Phase 1/2
Ages
18 years and older
Sex
All
Healthy volunteers
Not accepted
Sponsor
Memorial Sloan Kettering Cancer Center
Last updated on ClinicalTrials.gov
May 18, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

New Jersey · 3

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) · Basking Ridge, NJ
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) · Middletown, NJ
  • Memorial Sloan Kettering Bergen (All Protocol Activities) · Montvale, NJ

New York · 4

  • Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities) · Commack, NY
  • Memorial Sloan Kettering Westchester (All Protocol Activities) · Harrison, NY
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) · New York, NY
  • Memorial Sloan Kettering Nassau (All Protocol Activities) · Uniondale, NY

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.